admin@corsonis.com

3205 PO Box 443, Melbourne Victoria

Pending

2016-11-07

2021-06-30

2018-03-26


Corsonis, a medical technology company, is commercializing a non-invasive, portable and scalable platform technology which operates in the cardiac diagnostics, monitoring and telehealth space. Our flagship products, Cor-A and Cor-S, will initially allow healthcare professionals to screen for irregular heart rhythms (atrial fibrillation) and structural heart disease (valvular heart disease) at the bedside reducing the need for further invasive and expensive cardiac testing. A consumer version will be available for home use allowing for remote monitoring (reporting to Electronic Health Records and Specialists) and telemedicine.

Corsonis, a medical technology company, is commercializing a non-invasive, portable and scalable platform technology which operates in the cardiac diagnostics, monitoring and telehealth space. Our flagship products, Cor-A and Cor-S, will initially allow healthcare professionals to screen for irregular heart rhythms (atrial fibrillation) and structural heart disease (valvular heart disease) at the bedside reducing the need for further expensive cardiac testing and allow clinicians to make quicker more accurate decisions. A consumer version (Cor-S Lite) will be available for home use allowing for remote monitoring (reporting to Electronic Health Records and Specialists) and telemedicine.

Cor-A is a device-agnostic platform which receives biometric data from the Cor-S and Cor-S Lite devices. It contains a suite of algorithms which displays information through simple decision support tools to allow healthcare professionals triage, screen and diagnose cardiovascular disease. Furthermore, the platform contains APIs to allow integration of third-party platforms such as EMR and telemedicine providers. Cor-S is medical device which is applied to a patients chest wall and collects cardiac biometric data. This devices sends information via bluetooth to any connected smart device or computer. Using Cor-A, it is expected the platform will provide clinicans and patients with reports simliar to Electrocardiography and Echocardiography reports.